- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02245711
Cell Therapy in Limb Girdle Muscular Dystrophy
October 23, 2018 updated by: Neurogen Brain and Spine Institute
Intrathecal Autologous Mononuclear Cell Therapy for Limb Girdle Muscular Dystrophy
The purpose of this study was to study the effect of stem cell therapy on Limb Girdle Muscular Dystrophy patients.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maharashtra
-
Navi Mumbai, Maharashtra, India, 400706
- Neurogen brain and spine institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 60 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age group of 15 years-60 years
- limb girdle muscular dystrophy diagnosed on the basis of clinical presentation
- Electromyographic and Nerve Conduction velocity findings
Exclusion Criteria:
- presence of respiratory distress
- presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus
- malignancies
- acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction < 30%
- pregnancy or breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Stem Cell
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Functional Independence Measure (FIM) scale
Time Frame: 1 year
|
Functional Independence Measure scale assesses the patients ability to carry out activities of daily living.
At the follow up of 1 year, every patient in this study will be reevaluated on this scale.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Manual Muscle Testing (MMT)
Time Frame: 1 year
|
Manual muscle testing is a procedure for the evaluation of the function and strength of individual muscles and muscle groups based on the effective performance of a movement in relation to the forces of gravity and manual resistance.
On the follow up after 1 year, every patient will be reassessed on MMT to record changes in their muscle strength after stem cell therapy.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2010
Primary Completion (Actual)
January 1, 2015
Study Completion (Actual)
June 1, 2015
Study Registration Dates
First Submitted
September 12, 2014
First Submitted That Met QC Criteria
September 17, 2014
First Posted (Estimate)
September 22, 2014
Study Record Updates
Last Update Posted (Actual)
October 25, 2018
Last Update Submitted That Met QC Criteria
October 23, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NGBSI-12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Limb Girdle Muscular Dystrophy
-
University Hospital of North NorwayUniversity of Tromso; Norwegian Muscle Disease Association (FFM); Norwegian National... and other collaboratorsActive, not recruitingMuscular Dystrophies | Limb Girdle Muscular Dystrophy | Limb Girdle Muscular Dystrophy, Type 2I | Limb Girdle Muscular Dystrophy R9 FKRP-relatedNorway
-
ML Bio Solutions, Inc.Active, not recruitingLimb-Girdle Muscular Dystrophy Type 2I (LGMD2I)United States, Netherlands, United Kingdom, Denmark, Norway, Australia, Germany, Italy
-
Virginia Commonwealth UniversityMuscular Dystrophy AssociationRecruitingLGMD2E | LGMD2I | LGMD2A | LGMD2B | LGMD2C | LGMD1B | LGMD1C | LGMD1D | LGMD1E | LGMD1F | LGMD1G | LGMD1H | LGMD2D | LGMD2F | LGMD2G | LGMD2J | LGMD2K | LGMD2L | LGMD2M | LGMD2N | LGMD2O | LGMD2P | LGMD2Q | LGMD2S | LGMD2T | LGMD2U | LGMD2W | LGMD2X | LGMD2YUnited States
-
Lindsay AlfanoCompletedLimb-Girdle Muscular Dystrophy Type 2A | Limb-Girdle Muscular Dystrophy, Type 2EUnited States
-
Virginia Commonwealth UniversityUniversity of Colorado, Denver; Washington University School of Medicine; University... and other collaboratorsActive, not recruitingLimb Girdle Muscular Dystrophy | Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A | Limb Girdle Muscular Dystrophy Type R1 | LGMD2AUnited States
-
Sarepta Therapeutics, Inc.WithdrawnMuscular Dystrophies, Limb-GirdleUnited States
-
Rigshospitalet, DenmarkCompletedBecker Muscular Dystrophy | Limb-Girdle Muscular Dystrophy Type 2IDenmark
-
Cooperative International Neuromuscular Research...Carolinas Medical Center lead study siteCompletedBecker Muscular Dystrophy | Limb-Girdle Muscular Dystrophy, Type 2A (Calpain-3 Deficiency) | Limb-Girdle Muscular Dystrophy, Type 2B (Miyoshi Myopathy, Dysferlin Deficiency) | Limb-Girdle Muscular Dystrophy, Type 2I (FKRP-deficiency)United States
-
Nationwide Children's HospitalMyonexus TherapeuticsRecruitingLimb-Girdle Muscular Dystrophy, Type 2EUnited States
-
IRCCS San Camillo, Venezia, ItalyUniversita di Verona; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico and other collaboratorsEnrolling by invitationCalpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2AItaly
Clinical Trials on Stem Cell
-
China Medical University HospitalUnknownIschemia | Ischemic Stroke | Brain Ischemia | Infarction, Middle Cerebral Artery | Ischaemic Cerebral InfarctionTaiwan
-
National Heart Institute, MexicoNational Center of Blood Transfusion Mexico.UnknownAcute Myocardial InfarctionMexico
-
Royan InstituteCompletedOsteoarthritisIran, Islamic Republic of
-
Northwestern UniversityTerminated
-
Mongolian National University of Medical SciencesNot yet recruiting
-
Hackensack Meridian HealthCompletedDiabetes Mellitus Type 1United States
-
Royan InstituteCompletedCerebral PalsyIran, Islamic Republic of
-
Al-Azhar UniversityCompletedPremature Ovarian FailureEgypt
-
Mayo ClinicUniversity of Alabama at Birmingham; University of Mississippi Medical CenterCompletedChronic Kidney Disease | Renal Artery Stenosis | Ischemic Nephropathy | Renovascular DiseaseUnited States
-
Royan InstituteCompletedOsteoarthritisIran, Islamic Republic of